Latest ArticlesTo investigate the effect of hormone combined with cyclophosphamide in the treatment of membranous nephropathy(MN) on serum albumin(ALB) and 24-hour urine protein(24hUP).
A total of 126 patients with MN who received treatment in Linquan county people's hospital from November 2021 to December 2024 were selected as the research subjects, including 63 cases in the observation group and 63 cases in the control group. The control group received hormone therapy alone, while the observation group received additional cyclophosphamide on the basis of the control group treatment. Clinical efficacy, serum ALB, 24hUP, urine albumin-to-creatinine ratio(UACR), lipid metabolism indicators, and adverse reaction rates were compared between the two groups.
After treatment, the total e ff ective rate was signi ficantly higher in the observation group than the control group(80.95% vs. 60.32%, P<0.05).Serum ALB levels were increased in both groups compared with those before treatment (P<0.05), and the observation group showing higher level than the control group(P<0.05). 24hUP levels decreased in both groups, and the observation group exhibiting lower level than the control group(P<0.05). After treatment, the levels of mALB, UACR, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were lower in both groups than those before treatment(P<0.05), and the observation group showing greater reduction than the control group(P<0.05). No statistically significant difference was observed in adverse reaction rates between the two groups(P>0.05).
Hormone combined with cyclophosphamide demonstrates superior efficacy in MN patients and can further improve serum ALB and 24hUP levels.
As a cutting-edge and potential novle class of anti-tumor drug, antibody-drug conjugates(ADC)have shown significant efficacy in a variety of tumor treatments. However, with the widespread use of ADC, the related adverse reactions have attracted more and more attention. Interstitial lung disease(ILD) is a serious and life-threatening adverse reactions, which is usually characterized by progressive dyspnea, cough, chest pain, hypoxemia and low-grade fever. The mechanism of ADC-related ILD is complex, involving multi-dimensional factors, and due to the lack of specific diagnostic criteria of ILD, high vigilance must be maintained in clinical practice, problems should be identified early and timely intervention. This review aims to sort out the pathogenesis, diagnostic evaluation and management strategies of ADC-related ILD, helping clinicians understand and master the characteristics of pulmonary toxicity of ADC, so as to reduce and avoid serious adverse reactions and ensure the effectiveness and safety of ADC therapy in clinical application.
The prevalence and incidence of obesity-related type 2 diabetes mellitus(T2DM) and non-alcoholic fatty liver disease(NAFLD) in our country are constantly increasing. Obesity T2DM/NAFLD not only increases the risk of cardiovascular disease, but is also closely related to a variety of malignant tumors, endocrine diseases and chronic kidney disease. At present, there are no specific preventive or therapeutic drugs for obesity T2DM/NAFLD. Semaglutide has been approved for weight reduction in China . It has significant research significance and application prospects for the prevention and treatment of obesity T2DM/NAFLD by improving insulin resistance, lowering blood sugar and blood lipids, reducing body weight, reducing hepatic steatosis and improving liver fibrosis.
Mycoplasmal pneumoniae pneumonia(MPP) is one of the most common etiological types of community-acquired pneumonia in childhood. In recent years, the incidence of macrolide-resistant MPP(MRMP) has shown a significantly increasing trend. With the entry of coronavirus disease 2019 into the seasonal epidemic mode, the incidence of MPP in children shows a significant upward trend. Macrolide antibiotics are the preferred anti-infective drugs for children with MPP, with remarkable therapeutic effects. Based on the epidemic trend, occurrence mechanism and key points of early diagnosis of MRMP in children, this paper reviewed the latest progress in the mechanism of action, implementation plan,efficacy and safety of new tetracycline drugs in the treatment of MRMP in children, providing a reference for clinical practice.
B-cell acute lymphoblastic leukemia(B-ALL) ranks first in incidence among newly diagnosed childhood malignancies. Current clinical treatment primarily relies on conventional chemotherapy, which is limited by poor tolerance and suboptimal long-term prognosis. Blinatumomab, a novel immunotherapy drug, targets CD3 and CD19 antigens to activate T-cell-specific killing of leukemia cells. It has demonstrated significant efficacy in relapsed/refractory B-ALL,minimal residual lesion clearance, and bridging hematopoietic stem cell transplantation. However, its clinical application is constrained by adverse reactions such as cytokine release syndrome and neurotoxicity. This review systematically summarized blinatumomab's mechanism of action, clinical application advancements, adverse effects, management strategies, and explored the future research directions, aiming to provide theoretical insights for optimizing precision therapy in B-ALL.
Kawasaki disease(KD) is an acute, self-limiting, multi-system vasculitic syndrome. It is the leading cause of acquired heart disease in children in developed countries. Coronary artery aneurysms are its most serious complication and can trigger long-term cardiovascular events. In recent years, the understanding of the pathogenesis of KD has shifted from the single pathogen hypothesis to an immune-disordered disease caused by microorganisms. Based on the individualized treatment model of KD with risk stratification, this paper systematically reviewed the latest advances in pharmacotherapy for KD, and prospected the future research directions, aiming to provide reference for clinical medication.
To explore the effect and molecular mechanism of catechins in improving age-related macular degeneration(AMD) by targeting and inhibiting oxidative stress mediated by DNA polymerase delta interacting protein(Poldip)2.
The possible pharmacological targets of catechins were detected by network pharmacology and molecular docking. Human retinal pigment epithelial cells(ARPE-19) were treated with(300 μM) H2O2 to establish the AMD cell model, which was divided into the normal control group, the AMD group, the AMD+low-dose catechin group(3 μM), and the AMD+high-dose catechin group(300 μM). Cell viability was detected using cell counting kit-8, and the levels of reactive oxygen species(ROS), malondialdehyde(MDA), superoxide dismutase(SOD) and glutathione(GSH) were determined. The expression levels of β -galactosidase, Poldip2, NADPH oxidase(NOX)4 and ROS were detected by enzyme-linked immunosorbent assay(ELISA).
Catechins may alleviate AMD by targeting and inhibiting Poldip2. Different concentrations of catechins promote the proliferation of RPE cells in a dose-dependent manner. Compared with the normal control group, the levels of ROS and MDA in the AMD group cells were significantly increased, while the levels of SOD and GSH were significantly decreased(P<0.05). Compared with the AMD group, the levels of ROS and MDA in the two groups treated with catechins were significantly decreased, while the levels of SOD and GSH were significantly increased(P<0.05). The levels of β -galactosidase, Poldip2 and NOX4 in the AMD group cells were significantly increased, while those in the two groups treated with catechins were significantly decreased(P<0.05).
Catechins improve AMD by targeting and inhibiting the Poldip2-NOX4-H2O2 pathway, reducing ROS generation, enhancing the antioxidant capacity of retinal pigment epithelial cells, and delaying cellular aging.
To investigate the effect of triple vitamin therapy(folic acid, vitamin B6, and mecobalamin) on cognitive function in patients with white matter lesions and hyperhomocysteinemia.
A total of 89 patients with white matter lesions and hyperhomocysteinemia were prospectively enrolled and divided into a cognitive impairment group[Montreal cognitive assessment(MoCA)<26, n=66)] and a non-cognitive impairment group(MoCA≥26, n=23),based on the baseline MoCA scores. All patients received triple vitamin therapy for 12 months. The baseline characteristics between the two groups were compared, the cognitive function changes after treatment were evaluated, and the influencing factors of cognitive improvement (defined as MoCA score increase≥2 points) were analyzed by logistic regression.
Except for MoCA scores[cognitive impairment group: 20.0(17.0, 23.0)points vs. non-cognitive impairment group: 26.0(26.0, 27.0)points, P<0.001], there were no statistically significant differences between the two groups in age, gender, education level, vascular risk factors, laboratory indicators, and Fazekas scores(P>0.05). After 12 months of treatment, serum total homocysteine levels significantly decreased(P<0.001). The change in MoCA total score from baseline was 1.0(-2.0, 3.0) points(P=0.126) in the cognitive impairment group and -1.0(-3.0, 1.0) points(P=0.053) in the non-cognitive impairment group, with a statistically significant difference between the two group(P=0.020).Subdomain analysis showed that the cognitive impairment group had significant improvements compared to the baseline in visuospatial and executive function(P<0.001), naming(P<0.001), attention(P=0.015), and abstraction(P=0.013),with changes in visuospatial and executive functio(P=0.004) and naming(P=0.017) being significantly superior to those in the non-cognitive impairment group. Multivariate logistic regression analysis showed that baseline MoCA score was an independent predictor of cognitive improvement(odds ratio=0.76, 95% Wald confidence interval: 0.64-0.87, P<0.001).
Triple vitamin therapy for 12 months can improve specific cognitive functions in patients with white matter lesions and hyperhomocysteinemia, especially in patients with baseline cognitive impairment. Visuospatial and executive function, naming, abstraction, and attention have improved significantly. Patients with poorer baseline cognitive function have greater room for improvement.
To observe the adjuvant effect of modified Guizhi Shaoyao Zhimu decoction on patients with knee osteoarthritic synovitis of wind-cold-damp arthralgia syndrome.
A total of 102 patients with knee osteoarthritic synovitis of wind-cold-damp arthralgia syndrome who were admitted to our hospital from November 2022 to December 2023 were selected as the research subjects and randomly divided into the control group and the observation group, with 51 cases in each group. The control group received conventional treatment and extracorporeal shock wave therapy, while the observation group was given modified Guizhi Shaoyao Zhimu decoction on the basis of the treatment of the control group. The therapeutic effects, total score of traditional Chinese medicine(TCM) symptoms, western ontario and McMaster universities osteoarthritis index(WOMAC) score, hospital for special surgery knee score(HSS), joint effusion score, synovial thickness score, changes in serum inflammatory factor levels and occurrence of adverse reactions were compared between the two groups.
After treatment, the total effective rate of the observation group was higher than that of the control group (94.12% vs. 80.39%, P<0.05). After treatment, the total score of TCM symptoms,WOMAC score, HSS, joint effusion score and synovial thickness score of the observation group were all better than those of the control group, and the levels of inflammatory factors were all lower than those of the control group, with significant differences (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (3.92% vs. 5.88%), but there was no significant difference (P>0.05).
The modified Guizhi Shaoyao Zhimu decoction has a good effect and is safe and reliable in the adjuvant treatment of patients with knee osteoarthritic synovitis of wind-cold-damp arthralgia syndrome.
To explore the effects of cetirizine combined with montelukast sodium on sleep, quality of life,immunity, inflammatory factors and safety in children with cough variant asthma(CVA).
A total of 71 children with CVA admitted to our hospital from December 2022 to October 2024 were selected as the research subjects and randomly divided into the experimental group of 35 cases and the control group of 36 cases. Both groups received basic treatment. The control group was treated with montelukast sodium, and the experimental group was treated with cetirizine on this basis. The treatment course for both groups was one week. The apnea-hypopnea index, the lowest nocturnal blood oxygen saturation, quality of life and inflammatory factors of the two groups before and after treatment were detected,and the occurrence of adverse reactions was statistically analyzed.
After treatment, the minimum nocturnal blood oxygen saturation, immunoglobulin(Ig)A, interferon-γ, cluster of differentiation(CD)4+, CD4+/CD8+ in both groups increased compared with those before treatment, and the experimental group was higher than the control group. The differences were significant(P<0.05). The scores of sleep disorders, physical symptoms, poor mood, daytime functional status and total score in both groups after treatment were lower than those before treatment. The scores in the experimental group were lower than those in the control group, and the differences were significant(P<0.05). The apnea-hypopnea index, C reactive protein, monocyte chemoattractant protein-1, interleukin(IL)-4, transforming growth factor -β, vascular endothelial growth factor, IgE, IL-13, and CD8+ in both groups decreased compared with those before treatment, and the experimental group was lower than the control group, with significant differences(P<0.05). There was no significant difference in the total incidence of abdominal pain and diarrhea, nausea and vomiting, rash and dizziness between the two groups(P>0.05).
Cetirizine combined with montelukast sodium in the treatment of children with CVA can improve sleep structure, enhance quality of life and immune function, reduce the levels of inflammatory factors, and has good safety.